Table 1.
Characteristics of patients sampled for assessment of claims-based algorithm performance compared with eligible patients and full cohort
| Characteristic | Chart-review patients (N=400) |
Chart-review eligible patients (N=6,460) |
All Patients (N=13,472) |
|---|---|---|---|
| Mean Age at Diagnosis (SD, median) | 65 (14, 65) | 60 (14, 58) | 61 (13, 61) |
| Age ≥ 65 Years (n, %) | 207 (52%) | 2326 (36%) | 5521 (41%) |
| Year of Cancer Diagnosis (n, %) | |||
| 1999 | 28 (7%) | 644 (10%) | 1281 (10%) |
| 2000 | 40 (10%) | 593 (9%) | 1268 (9%) |
| 2001 | 41 (10%) | 720 (11%) | 1595 (12%) |
| 2002 | 44 (11%) | 727 (11%) | 1608 (12%) |
| 2003 | 38 (10%) | 714 (11%) | 1520 (11%) |
| 2004 | 42 (11%) | 702 (11%) | 1394 (10%) |
| 2005 | 63 (16%) | 769 (12%) | 1564 (12%) |
| 2006 | 59 (15%) | 770 (12%) | 1606 (12%) |
| 2007 | 45 (11%) | 821 (13%) | 1636 (12%) |
| Charlson score | |||
| 0 | 229 (57%) | 4506 (70%) | 9340 (69%) |
| 1 | 46 (12%) | 883 (14%) | 1925 (14%) |
| 2 | 53 (13%) | 640 (10%) | 1393 (10%) |
| 3+ | 72 (18%) | 431 (7%) | 814 (6%) |
| Race (n, %) | |||
| White | 299 (79%) | 5331 (84%) | 11312 (86%) |
| Black/African American | 67 (18%) | 735 (12%) | 1336 (10%) |
| Other | 15 (4%) | 259 (4%) | 550 (4%) |
| Worst AJCC stage (n, %) | |||
| 1 | 48 (16%) | 520 (10%) | 6354 (55%) |
| 2a | 126 (41%) | 2575 (47%) | 2601 (23%) |
| 2b | 56 (18%) | 1108 (20%) | 1110 (10%) |
| 3/4 | 75 (25%) | 1281 (23%) | 1467 (13%) |
| Unknown | 95 | 976 | 1940 |
| Surgical treatment (n, %) | 324 (81%) | 6089 (95%) | 12812 (95%) |
| Radiation treatment (n, %) | 141 (39%) | 3315 (42%) | 7486 (57%) |
| Chemotherapy treatment | |||
| None | 157 (39%) | 1827 (28%) | 6240 (46%) |
| Anthracycline only | 78 (20%) | 2937 (46%) | 3847 (27%) |
| Trastuzumab only | 6 (2%) | 98 (2%) | 157 (1%) |
| Anthracycline + trastuzumab | 74 (19%) | 385 (6%) | 470 (4%) |
| Other | 85 (21%) | 1213 (19%) | 2748 (20%) |